In the following article, we will explore the topic of Propanidid from different perspectives and approaches. _Var1 is a topic that has sparked interest and debate over time, and its relevance and impact extends to various areas of daily life. Through a detailed and exhaustive analysis, we will take a look at the history, current trends, and future of Propanidid, as well as its influence on society in general. With interviews with experts, relevant data and illustrative examples, we aim to offer a complete and enlightening vision of this fascinating and important topic.
![]() | |
Clinical data | |
---|---|
Trade names | Epontol |
AHFS/Drugs.com | International Drug Names |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.014.384 |
Chemical and physical data | |
Formula | C18H27NO5 |
Molar mass | 337.416 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Propanidid is an ultra short-acting phenylacetate general anesthetic. It was originally introduced by Bayer in 1963[2] but anaphylactic reactions caused it to be withdrawn shortly afterwards.
Even though Cremophor EL has been shown to cause anaphylactic reactions in humans in several cases (both when given intravenously and orally), it is still debated whether propanidid itself may have contributed to the reactions.
It has been argued that the toxic effects or reactions to propanidid (and Althesin) were due to the drugs themselves.[3] Several cases of negative reactions have been recorded for different drugs using Cremophor EL as solubilizer, suggesting that the negative reactions were mainly caused by Cremophor and not by the drug substances themselves.